Clinical Trial Update: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone [Phase 2]

View source ↗

Summary

This Phase 2 study in schizophrenia evaluated ACP-103 in combination with haloperidol and risperidone and has completed, focusing on antipsychotic effects and m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ACP-103 (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED